CN101273014B - 作为多巴胺神经传递调节剂的3，5-二取代的苯基-哌啶 - Google Patents

作为多巴胺神经传递调节剂的3，5-二取代的苯基-哌啶 Download PDF

Info

Publication number
CN101273014B
CN101273014B CN2006800352682A CN200680035268A CN101273014B CN 101273014 B CN101273014 B CN 101273014B CN 2006800352682 A CN2006800352682 A CN 2006800352682A CN 200680035268 A CN200680035268 A CN 200680035268A CN 101273014 B CN101273014 B CN 101273014B
Authority
CN
China
Prior art keywords
disorder
nervous system
central nervous
compounds
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800352682A
Other languages
English (en)
Chinese (zh)
Other versions
CN101273014A (zh
Inventor
C·索内松
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of CN101273014A publication Critical patent/CN101273014A/zh
Application granted granted Critical
Publication of CN101273014B publication Critical patent/CN101273014B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800352682A 2005-10-13 2006-10-12 作为多巴胺神经传递调节剂的3，5-二取代的苯基-哌啶 Expired - Fee Related CN101273014B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0502254.6 2005-10-13
SE0502254A SE529246C2 (sv) 2005-10-13 2005-10-13 Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
PCT/EP2006/009866 WO2007042295A1 (en) 2005-10-13 2006-10-12 3, 5-disubstituted phenyl-piperidines as mdulators of dopamine? neurotransmission

Publications (2)

Publication Number Publication Date
CN101273014A CN101273014A (zh) 2008-09-24
CN101273014B true CN101273014B (zh) 2011-01-12

Family

ID=37467527

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800352682A Expired - Fee Related CN101273014B (zh) 2005-10-13 2006-10-12 作为多巴胺神经传递调节剂的3，5-二取代的苯基-哌啶

Country Status (23)

Country Link
US (1) US8501777B2 (cg-RX-API-DMAC7.html)
EP (1) EP1948606B1 (cg-RX-API-DMAC7.html)
JP (1) JP4857346B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080046720A (cg-RX-API-DMAC7.html)
CN (1) CN101273014B (cg-RX-API-DMAC7.html)
AT (1) ATE494277T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006301432B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0617355A2 (cg-RX-API-DMAC7.html)
CA (1) CA2625663A1 (cg-RX-API-DMAC7.html)
DE (1) DE602006019470D1 (cg-RX-API-DMAC7.html)
DK (1) DK1948606T3 (cg-RX-API-DMAC7.html)
ES (1) ES2358537T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110196T1 (cg-RX-API-DMAC7.html)
IL (1) IL189298A0 (cg-RX-API-DMAC7.html)
MY (1) MY143241A (cg-RX-API-DMAC7.html)
NO (1) NO20082174L (cg-RX-API-DMAC7.html)
NZ (1) NZ566015A (cg-RX-API-DMAC7.html)
PL (1) PL1948606T3 (cg-RX-API-DMAC7.html)
RU (1) RU2418787C2 (cg-RX-API-DMAC7.html)
SE (1) SE529246C2 (cg-RX-API-DMAC7.html)
UA (1) UA93380C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007042295A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200802238B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
DE602005021641D1 (de) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US8524766B2 (en) * 2008-04-29 2013-09-03 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
AU2009242095A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3503890B1 (en) * 2016-08-24 2024-12-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating dystonias
CN111343982A (zh) * 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046146A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2006040156A1 (en) * 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (cg-RX-API-DMAC7.html) * 1964-04-14
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
FR1459013A (fr) 1964-08-05 1966-04-29 Allen & Hanburys Ltd Procédé de préparation de dérivés de la 4-phényl-pipéridine
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ZA7546B (en) 1974-01-21 1976-08-25 Parke Davis & Co New antibacterial amide compounds and methods for their production
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) * 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2459797A2 (fr) 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4333942A (en) * 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) * 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) * 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
ES2157204T3 (es) 1991-04-17 2001-08-16 Upjohn Co Derivados de (s)-3-fenilpiperidina sustituidos, su preparacion y uso como antagonistas de autorreceptores de dopamina.
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0533268B1 (en) 1991-09-18 2001-08-16 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
EP0659743A1 (en) 1993-12-27 1995-06-28 Hoechst Aktiengesellschaft Piperidine derivatives as inhibitors of platelet aggregation and their preparation
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
AU6470096A (en) 1995-07-19 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US5892041A (en) * 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
SK283394B6 (sk) 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
JP2000086603A (ja) 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体
DE60025604T2 (de) 1999-06-22 2006-07-27 Neurosearch A/S Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1313477A4 (en) 2000-07-15 2004-03-03 Smithkline Beecham Corp COMPILATIONS AND METHODS
US7186715B2 (en) 2001-01-08 2007-03-06 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
BRPI0511907A8 (pt) 2004-06-08 2018-05-02 A Carlsson Res Ab novos derivados de fenilpiperidinas/piperazinas dissubstituídos como moduladores da neurotransmissão de dopamina
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
DE602005021641D1 (de) * 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
CN101031300A (zh) 2004-10-01 2007-09-05 默克公司 用于治疗或预防糖尿病的作为二肽基肽酶－ⅳ抑制剂的氨基哌啶化合物
CN101268077A (zh) * 2005-08-05 2008-09-17 阿斯利康(瑞典)有限公司 三环苯并咪唑及其作为代谢型谷氨酸受体调节剂的用途
EP1963268B1 (en) 2005-12-07 2010-12-01 NSAB, Filial af NeuroSearch Sweden AB, Sverige Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046146A1 (en) * 1999-12-22 2001-06-28 A. Carlsson Research Ab New modulators of dopamine neurotransmission
WO2006040156A1 (en) * 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines

Also Published As

Publication number Publication date
JP4857346B2 (ja) 2012-01-18
DK1948606T3 (da) 2011-04-04
KR20080046720A (ko) 2008-05-27
US8501777B2 (en) 2013-08-06
AU2006301432A1 (en) 2007-04-19
PL1948606T3 (pl) 2011-08-31
SE529246C2 (sv) 2007-06-12
EP1948606A1 (en) 2008-07-30
JP2009511525A (ja) 2009-03-19
MY143241A (en) 2011-04-15
DE602006019470D1 (de) 2011-02-17
EP1948606B1 (en) 2011-01-05
CA2625663A1 (en) 2007-04-19
SE0502254L (sv) 2007-04-14
HK1125097A1 (en) 2009-07-31
CN101273014A (zh) 2008-09-24
BRPI0617355A2 (pt) 2011-07-26
RU2418787C2 (ru) 2011-05-20
NZ566015A (en) 2010-11-26
ATE494277T1 (de) 2011-01-15
RU2008108618A (ru) 2009-11-20
WO2007042295A1 (en) 2007-04-19
US20080234321A1 (en) 2008-09-25
HRP20110196T1 (hr) 2011-05-31
AU2006301432B2 (en) 2011-12-15
ZA200802238B (en) 2009-10-28
NO20082174L (no) 2008-07-11
IL189298A0 (en) 2008-06-05
ES2358537T3 (es) 2011-05-11
UA93380C2 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
CN101273014B (zh) 作为多巴胺神经传递调节剂的3，5-二取代的苯基-哌啶
CN101076517B (zh) 作为多巴胺神经传递调节剂的取代的哌啶类
EP1773772B1 (en) New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
US7763639B2 (en) Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
HK1125097B (en) 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
CN1997630B (zh) 作为多巴胺神经传递调节剂的二取代的苯基哌啶类/哌嗪类
MX2008004603A (es) Fenil-piperidinas 3,5-disustituidas como moduladores de neurotransmision de dopamina
US7851629B2 (en) Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
JP2008501748A (ja) ドーパミン神経伝達のモジュレーターとしての新規な置換されたピペリジン
HK1105153A (en) New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
HK1105142A (en) New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090206

Address after: Denmark and Rupp

Applicant after: Nsab Af Neurosearch Sweden AB

Address before: Gothenburg

Applicant before: Carlsson Res AB A.

ASS Succession or assignment of patent right

Owner name: NSAB SWEDEN S NERVE RESEARCH BRANCH CORPORATION

Free format text: FORMER OWNER: SWEDEN S NERVE RESEARCH

Effective date: 20090206

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125097

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1125097

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110112

Termination date: 20131012